V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Veracyte Executive Compensation (FY25)

VCYT · Executive and director compensation, fiscal 2022 to 2025

The Veracyte brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 19, 2026Latest filing (8-K): June 11, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Veracyte brief$1,500Get the executive brief
287 figures on this page: 280 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Marc Stapley
Latest say-on-pay support
=
June 10, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Marc Stapley: $6,816,368 → $7,421,877 (8.9% higher)
CEO pay ratio: 44:1 → 38:1 (13.6% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Veracyte's chief executive and what were they paid?
Marc Stapley, Chief Executive Officer, received $7,421,877 in total compensation for fiscal 2025. Compared with the $6,816,368 reported for fiscal 2024, Stapley's total was 8.9% higher.
What was Veracyte's say-on-pay result?
The say-on-pay proposal drew 97.4% of votes cast including abstentions in favor at the meeting held June 10, 2026 for fiscal 2025.
Which companies are in Veracyte's peer group?
The disclosed peer group names 10x Genomics, Adaptive Biotechnologies, Amicus Therapeutics, BioCryst Pharmaceuticals and CareDX, among others.
What is Veracyte's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 38:1, against median employee compensation of $196,646.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Marc Stapley
Chief Executive Officer
◇—◇◇◇—◇◇
Rebecca Chambers
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Marc Stapley
Chief Executive Officer
◇—◇◇◇—◇◇
Phillip Febbo
Chief Scientific Officer and Chief Medical Officer
◇—◇◇◇—◇◇
Rebecca Chambers
Chief Financial Officer
◇—◇◇◇—◇◇
Annie McGuire
General Counsel
◇—◇◇◇—◇◇
John Leite
Global Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Marc Stapley
Chief Executive Officer
◇—◇—◇—◇◇
Rebecca Chambers
Chief Financial Officer
◇—◇—◇—◇◇
John Leite
Global Chief Commercial Officer
◇—◇—◇—◇◇
Annie McGuire
General Counsel and Chief People Officer
◇—◇—◇—◇◇
Phillip Febbo
Chief Scientific Officer and Chief Medical Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Marc Stapley
Chief Executive Officer
◇—◇—◇—◇◇
John Leite
Global Chief Commercial Officer
◇—◇—◇—◇◇
Rebecca Chambers
Chief Financial Officer
◇—◇—◇—◇◇
Annie McGuire
General Counsel and Head of Market Access
◇—◇—◇—◇◇
Phillip Febbo
Chief Scientific Officer and Chief Medical Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Annie McGuireRSU◇——◇——◇
Annie McGuirePSU◇◇◇—◇—◇
John LeitePSU◇◇◇—◇—◇
John LeiteRSU◇——◇——◇
Marc StapleyPSU◇◇◇—◇—◇
Marc StapleyRSU◇——◇——◇
Phillip FebboRSU◇——◇——◇
Phillip FebboPSU◇◇◇—◇—◇
Rebecca ChambersRSU◇——◇——◇
Rebecca ChambersPSU◇◇◇—◇—◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
John LeiteRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/6/2033
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇9/1/2032
PSU◇◇——
Marc StapleyRSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇3/6/2033
Option◇—◇3/3/2032
Annie McGuirePSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇3/6/2033
RSU◇◇——
Option◇—◇2/28/2032
Phillip FebboOption◇—◇10/2/2033
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Rebecca ChambersRSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇3/6/2033
Option◇—◇3/3/2032
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
John Leite
Global Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Marc Stapley
Chief Executive Officer · Employment agreement · citing a 2021 filing
Equity acceleration on change in control◇
Clawback◇
Phillip Febbo
Chief Scientific Officer and Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert S. Epstein
Board chair
◇◇————◇
Jens Holstein
◇◇————◇
Evan Jones
◇◇————◇
Karin Eastham
◇◇————◇
Muna Bhanji
◇◇————◇
Brent Shafer
◇◇————◇
Tom Miller
◇◇————◇
Eliav Barr
◇◇————◇
Marc Stapley served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics TXG
  • Adaptive Biotechnologies ADPT
  • Amicus Therapeutics FOLD
  • BioCryst Pharmaceuticals BCRX
  • CareDX CDNA
  • Cytek Biosciences CTKB
  • Exact Sciences EXAS
  • Fulgent Genetics FLGT
  • Glaukos GKOS
  • Guardant Health GH
  • Maravai Lifesciences MRVI
  • Myriad Genetics MYGN
  • Natera NTRA
  • NeoGenomics NEO
  • Nevro NVRO
  • Pacific Biosciences of California PACB
  • Twist Bioscience TWST
  • Ultragenyx Pharmaceutical RARE
  • Vericel VCEL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 10, 2026=◇◇◇
2024June 17, 2025=◇◇◇
2023June 12, 2024=◇◇◇
2021June 15, 2022=◇◇◇
2020June 7, 2021=◇◇◇
2019June 5, 2020=◇◇◇
2018June 11, 2019=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Veracyte files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Veracyte disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Veracyte sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Veracyte's disclosed peer group is defensible, who names Veracyte back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
287 figures on this page: 280 cited to the filing that reported them, 7 calculated from figures it prints.
280 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001384101-26-000038
    Proposal No. 4 – Approval of Amendment to Veracyte, Inc.
  2. 0001384101-26-000021
    2025 Director Compensation · 2025 Outstanding Equity Awards at Fiscal Year-End · CEO Pay Ratio · Compensation Discussion and Analysis · and 3 more sections
  3. 0001384101-25-000083
    Proposal No. 5 – Approval of Amendment to Veracyte, Inc.
  4. 0001384101-25-000051
    Summary Compensation Table
  5. 0001384101-24-000093
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001384101-24-000057
    Summary Compensation Table
  7. 0001384101-23-000055
    Summary Compensation Table
  8. 0001384101-22-000086
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001384101-21-000102
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001384101-20-000083
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001384101-19-000066
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001384101-21-000139
    EX-10.8
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Veracyte executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/VCYT (accessed 2026).
Short form: data: Velarion

The Veracyte brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Veracyte and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Veracyte discloses

The companies named in VCYT's own disclosed peer group.

10x GenomicsAdaptive BiotechnologiesAmicus TherapeuticsBioCryst PharmaceuticalsCareDXCytek BiosciencesExact SciencesFulgent GeneticsGlaukosGuardant HealthMaravai LifesciencesMyriad GeneticsNateraNeoGenomicsNevroPacific Biosciences of CaliforniaTwist BioscienceUltragenyx PharmaceuticalVericel

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy